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Adeno-associated virus (AAV) is capable of mediating 
 retrograde viral transduction of central and peripheral 
neurons. This occurs at a relatively low efficiency, which we 
previously found to be dependent upon capsid serotype. 
We sought to augment retrograde transduction by pro-
viding increased axonal access to  peripherally  delivered 
AAV. Others have described utilizing full transection of 
peripheral nerves to mediate retro grade viral transduc-
tion of motor neurons. Here, we  examined the  ability 
of a transient demyelinating event to  modulate levels 
of retrograde AAV transduction. Transient demyelina-
tion does not cause lasting functional deficits.  Ethidium 
bromide (EtBr)–induced transient demyelination of the 
sciatic nerve resulted in significant elevation of retro-
grade transduction of both motor and sensory  neurons. 
Retrograde transduction levels of motor neurons and 
heavily myelinated, large-diameter sensory neurons 
increased at least sixfold following peripheral delivery 
of self-complementary AAV serotype 1 (scAAV1) and 
serotype 2 (scAAV2), when preceded by demyelination. 
These findings identify a means of significantly enhanc-
ing retrograde vector transport for use in experimental 
paradigms requiring either retrograde neuronal identifi-
cation and gene expression, or translational  treatment 
paradigms.
Received 4 August 2009; accepted 22 April 2010; published online  
25 May 2010. doi:10.1038/mt.2010.97
IntroductIon
Previously, we reported the ability of various serotypes of adeno-
associated virus (AAV) to retrogradely transduce spinal motor 
neurons of the cervical and lumbar spinal enlargements following 
peripheral administration.1 Indeed, several studies have reported 
retrograde transduction following peripheral administration 
using AAV, adenovirus, rabies virus, and rabies glycoprotein–
pseudotyped lentivirus.1–7 The advantages of retrograde transduc-
tion include gene expression in specific neuronal populations, 
limited immune response, and reduced central nervous system 
damage. One potential limiting factor in retrograde gene delivery, 
however, is the efficiency of the process. For example, to achieve 
transduction of large proportions of spinal motor neurons, viral 
uptake of AAV at nerve terminals requires injections to multiple 
muscle targets and large quantities of viral particles, in part due to 
vector transduction of local myotubes.8–10 Integrating an N-methyl 
d-aspartate receptor agonist peptide into the AAV2 capsid11 was 
able to increase the binding of AAV2 to the axon surface and sub-
stantially increase viral neuronal transduction. Because greater 
AAV binding to axons increased transduction, this was identi-
fied as a rate-limiting step in transduction of neurons via retro-
grade transport. Myelination of axons represents a barrier that 
may limit virion binding to the axonal surface and thus limit the 
efficiency of neuronal transduction following intranerve delivery. 
Previous studies utilizing intranerve delivery of viral particles 
have employed full transection of peripheral nerves in order to 
efficiently transduce motor neuron pools.5
In this study, we aimed to minimize axonal damage while 
increasing retrograde transduction efficiency following intranerve 
delivery of AAV. We utilized the gliotoxin ethidium bromide 
(EtBr) to transiently demyelinate motor axons before sciatic nerve 
delivery of AAV encoding green fluorescent protein (GFP). In 
previous studies, peripheral injection of the gliotoxic agents EtBr 
and lysophosphatidyl choline resulted in macrophage activation 
and the shedding of existing myelin, followed by Schwann cell 
proliferation and remyelination over a 2-week period that restores 
nerve conduction velocity and function.12–17 We now report sig-
nificant and substantial increases in the retrograde transduction 
efficiency of AAV when combined with EtBr injection.
results
Peripheral etBr injection enhances retrograde 
transduction of motor neurons
The efficiency of retrograde transduction of spinal motor  neurons 
by AAV-GFP serotypes 1 and 2 was assessed by immunohis-
tochemistry. Injection of 0.1% EtBr 1 week before viral delivery 
resulted in demyelination of the sciatic nerve and significant 
increases in numbers of GFP-expressing motor neurons when 
using either single-stranded rAAV or self-complementary AAV 
(scAAV) (paired t-tests; P < 0.05, n = 4 single-stranded rAAV1; 
P < 0.01, n = 5 scAAV1, P < 0.01, n = 3 scAAV2). The number 
of transduced motor neurons increased 6.1-fold following scAAV 
serotype 1 delivery to EtBr-injected sciatic nerve, compared to 
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scAAV1 injection into the contralateral nerve that was injected 
with phosphate-buffered saline (PBS) (Figure 1d). Similarly,  levels 
of scAAV serotype 2 transduction increased proportionately by an 
average of 6.5-fold when using EtBr (Figure 1d).
As demyelination proceeds, retrograde transduction 
of motor neurons increases
Myelin degradation was assessed over a 24-hour time period 
after EtBr injection. Following sciatic injection of EtBr, animals 
were sacrificed after time points of 15 minutes and 4, 8, 12, 16, or 
24 hours (n = 4/time point). Myelin in transverse sciatic nerve sec-
tions at the center of the EtBr injection was stained with gold (III) 
chloride.18 Quantitative analysis revealed that myelin density at 
the lesion epicenter rapidly decreased over 24 hours (Figure 2a). 
Based on these findings, another set of animals received injection 
of scAAV-GFP serotype 1 at time points of 15 minutes, 4, 8, 12, 
16, or 24 hours after injection of EtBr into the sciatic nerve. In 
these animals, there was a rapid increase in efficiency of retro-
grade transduction as a function of latency after EtBr injection 
(Figure 2).
etBr injection enhances retrograde transduction 
of sensory neurons
In addition to the effects of demyelination on the retrograde trans-
duction efficiency of motor neurons, similar increases in retrograde 















































Figure 1 etBr injection increases the retrograde transduction effi-
ciency of AAV. (a) GFP immunoreactive retrogradely transduced motor 
neurons in the lumber enlargement following sciatic injection of scAAV1. 
(b) Higher magnification stacked images from a. (c) Gold (III) chloride 
staining of transverse sciatic nerve sections demonstrates loss of myelin 
staining 3 weeks after 0.1% EtBr injection (black indicates myelin stain-
ing). (d) Increases in retrograde transduction following demyelination 
are indicated for each animal (in gray) with the mean values indicated 
by dashed lines ± SEM (brackets). Lines connect values from the same 
animals, comparing retrograde transduction efficiency of motor neurons 
after vector injection in the nondemyelinated sciatic nerve (PBS-injected) 
to transduction efficiency after vector injection in the demyelinated  sciatic 
nerve (EtBr-injected). Both serotype 1 and 2 exhibit similar increases in 
retrograde transduction (scAAV1 n = 5, scAAV2 n = 3). Bar = 500 μm (a), 
25 μm (b,c). ETBr, ethidium bromide; PBS, phosphate- buffered saline; 
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Figure 2 temporal relationship of etBr injection to retrograde trans-
duction efficiency. (a) Quantification of pixel density of gold (III) chlo-
ride myelin staining in transverse sciatic nerve sections demonstrates 
a reduction in myelination over time following EtBr injection (ANOVA, 
P < 0.0001). (b) As demyelination progresses, there is a corresponding 
increase in the number of retrogradely transduced motor neurons in 
the lumbar enlargement with scAAV1-eGFP delivery to the sciatic nerve 
(ANOVA, P < 0.0001). ANOVA, analysis of variance; eGFP, enhanced green 
fluorescent protein; EtBr, ethidium bromide; scAAV1, self- complementary 
AAV serotype 1.
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detected. Immunostaining of horizontal sections of the dorsal gray 
matter of lumbar spinal cord revealed significant increases in GFP 
labeling of sensory axons (Figure 3a). Pixel density measurements 
of GFP immunoreactive processes within the dorsal horn increased 
significantly to 34.3 ± 7.3% following EtBr injection, compared to 
3.9 ± 2.1% in contralateral dorsal horn that received scAAV1-GFP 
without EtBr injection (paired t-test; P < 0.005).
Within the dorsal root ganglia, increased GFP expression was 
detected in somata of neurons extending axons through EtBr-
injected nerve compared to contralateral controls (Figure 3b–d; 
paired t-test; P < 0.05). The total number of GFP immuno reactive 
dorsal root ganglia sensory neurons was 4.6-fold higher on the 
EtBr-injected side (Figure 3). Additionally, the percentage of 
those GFP immunoreactive neurons co-labeled for heavy-chain 
neurofilament (NF200; a marker of proprioceptive neurons) was 
higher following scAAV1-GFP injection to EtBr-treated sciatic 
nerve (48.9 ± 6.1%) compared to contralateral PBS-injected  sciatic 
nerve (29.2 ± 3.6%; Figure 3e; paired t-test; P < 0.05). The number 
of GFP, NF200 double-labeled cells was 8.5-fold higher following 
EtBr injection compared to PBS-injected nerve.
Applications of etBr/peripheral vector injection
We then tested practical applications of retrograde transduc-
tion  following EtBr injection. scAAV1 encoding neurotrophin-3 
(scAAV1-NT-3) was injected into the sciatic nerve 1 week following 
PBS or EtBr injection. Two weeks after viral injection, lumbar ven-
tral gray matter was dissected and enzyme-linked immuno sorbent 
assay revealed a significant increase in NT-3 levels in subjects 
injected with EtBr followed by scAAV1-NT-3, compared to scAAV1-
NT-3 without EtBr (30-fold increase; Figure 4a; Kruskal–Wallis χ2 
P < 0.005). EtBr (0.1%) injection alone did not induce detectable 
expression of NT-3 within ventral gray matter (Figure 4a).
Additionally, we examined the potential of increased viral 
transduction by scAAV1-GFP for in vivo axonal imaging. 
scAAV1-GFP retrograde transduction of large-diameter NF200-
immunoreactive dorsal root ganglia neurons following EtBr injec-
tion resulted in robust labeling of ascending sensory fibers visible 
by in vivo two-photon imaging (Figure 4b,c).
dIscussIon
Retrograde viral delivery is a useful strategy for therapeutic gene 
delivery aiming to eliminate damage caused by direct injection 































































Figure 3 etBr injection increases retrograde transduction of  sensory 
neurons. (a) Incoming sensory afferents projecting to the dorsal horn of 
the lumbar enlargement demonstrate robust GFP immunoreactivity fol-
lowing scAAV1-GFP retrograde transduction of 0.1% EtBr-injected sciatic 
nerve. (b,c) Retrogradely transduced sensory neurons in L5 dorsal root 
ganglia following scAAV1-GFP injection, 1 week after (b) PBS control injec-
tion or (c) 0.1% EtBr injection into the sciatic nerve. (d) Quantification of 
retrogradely transduced sensory neurons within L4/5 dorsal root ganglia 
illustrates significant increases in retrograde transduction of sensory neu-
rons following EtBr injection (paired t-test; *P < 0.05, n = 4). (e) The pro-
portion of retrogradely transduced sensory neurons immunoreactive for 
NF200 increases following EtBr injection (paired t-test; *P < 0.05, n = 4). 
Bar = 500 μm (a), 100 μm (b,c). DRG, dorsal root ganglion; EtBr, ethid-
ium bromide; GFP, green fluorescent protein; PBS, phosphate- buffered 
saline; scAAV1, self-complementary AAV serotype 1.
























Figure 4 Applications of etBr-enhanced retrograde transduction. 
(a) NT-3 levels after retrograde transduction with scAAV1-NT-3 are sig-
nificantly enhanced in lumbar ventral gray matter when viral delivery 
is preceded by 0.1% EtBr injection (Kruskal–Wallis χ2 P < 0.005). (b,c) 
Sensory neurons retrogradely transduced following sciatic demyelina-
tion are visible through the dorsal surface of the live mouse spinal cord 
in vivo using two-photon microscopy. Bar = 500 μm (b), 100 μm (c). 
ELISA, enzyme-linked immunosorbent assay; EtBr, ethidium bromide; 
scAAV1, self-complementary AAV serotype 1.
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a specific population of neurons. Improving relatively low retro-
grade transduction efficiency is necessary for transduction 
of large populations of neurons and for effective gene therapy 
of central and peripheral nervous system disorders. The use of 
transient demyelination of peripheral nerve, which is followed 
by complete functional recovery at electrophysiological and 
behavioral levels,14,15,17 is preferable to axonal transection.5 This 
is especially relevant for studies where a behavioral assay will be 
utilized to determine the functional outcome of a therapeutic 
treatment.
EtBr injection into the sciatic nerve increased retrograde 
transduction of spinal motor neurons by scAAV1-GFP and 
scAAV2-GFP by approximately sixfold. This increase in trans-
duction efficiency represents a significant advance in the utility 
of retrograde transduction for anatomical tracing and cell-specific 
gene expression in experimental paradigms. Further, this increase 
in efficiency likely surpasses a necessary practical threshold for 
the development of potential treatments of central nervous sys-
tem conditions including spinal cord injury and motor neuron 
degeneration. For example, we demonstrate significant elevation 
of NT-3 levels in the spinal cord following sciatic EtBr injec-
tion and retrograde transduction with scAAV1-NT-3. NT-3 is 
known to promote sprouting of descending corticospinal motor 
neurons,5,19 and local expression of NT-3 by spinal motor neurons 
could promote functional plasticity of injured corticospinal axons. 
Additionally, retrograde transduction has been utilized to reduce 
motor neuron death in models of amyotrophic lateral sclerosis 
via viral delivery of either small-interfering RNA directed against 
superoxide dismutase 1 mutant or genes encoding the trophic 
 factors insulin-like growth factor I or vascular endothelial growth 
factor.3,7 EtBr injection could potentially augment the therapeutic 
benefits of these treatments.
Over a 24-hour period following sciatic injection of 0.1% EtBr, 
there was a rapid decrease in myelin staining at the center of the 
gliotoxic lesion. Inversely related to this decrease was a significant 
rise in retrograde transduction of motor neurons. Although the 
full extent of demyelination proceeds longer than 24 hours after 
gliotoxic injection,13 rapid myelin clearance from the center of the 
lesion site was sufficient to mediate increased retrograde transduc-
tion even at this relatively early time point after EtBr injection.
Significant retrograde transduction of sensory neurons also 
occurred following EtBr injection. Although EtBr induced an 
increase in retrograde transduction of all sensory neurons by four-
fold, large-diameter, thickly myelinated, NF200-immunoreactive 
sensory neurons increased in retrograde transduction by eightfold. 
Transduction of large-diameter proprioceptive neurons may be 
especially useful as they are a key cell population in anatomical stud-
ies of sensory regeneration within the spinal cord. The superficial 
location of these long projection axons within the dorsal columns 
allows for their real-time study in vivo, in addition to postmortem 
histological studies. Peripheral delivery to dorsal root ganglia sen-
sory neurons may also be useful in therapies aiming to reduce allo-
dynia and hyperalgesia, modulating regeneration of sensory axons, 
and tracing or imaging ascending proprioceptive axons.
Whether EtBr could be used in human clinical trials remains 
to be established, because the compound is a mutagen when 
administered systemically at high doses. It is possible that lower 
doses injected directly into the nerve would have an acceptable 
safety profile, a subject that will be addressed in future studies. 
Alternative demyelinating compounds exist for potential clinical 
use, including lysophosphatidyl choline. In addition, the toler-
ability of transient demyelination on neurons undergoing patho-
logical degeneration in the context of a neurological disorder such 
as amyotrophic lateral sclerosis requires further study. Although 
animals subjected to transient demyelination readily recover 
nerve function,14,15,17 neurons in a degenerative condition may or 
may not tolerate transient demyelination. If conditions of both 
safety and tolerability could be met, transient demyelination with 
AAV vector administration could represent a substantial advance 
toward clinical applicability. These methods further present new 
tools for the study of retrograde gene delivery in animal models.
Methods
Viral production. Viral stocks were produced at the Vector Core at the 
University of North Carolina, Chapel Hill. Both single-stranded recom-
binant AAV and scAAV contained a human cytomegalovirus promoter, 
SV40 intron, enhanced GFP (or NT-3) transgene, and a SV40 polyA sig-
nal.1 Virions were produced via CaCl2 transfection of HEK 293 cells and 
CsCl-density-gradient purification as previously described.1,20,21 Viral titers 
determined by dot-blot DNA hybridization were diluted in Hank’s bal-
anced saline solution to 1.0 × 1012 viral particles/ml.
Animal subjects. Animal use in this research was approved by the 
Institutional Animal Care and Use Committee. For all surgical procedures, 
rats were anesthetized with isoflurane (Baxter, Deerfield, IL). For terminal 
procedures, rats were anesthetized with 2 ml/kg of a 25 mg/ml ketamine, 
1.3 mg/ml xylazine, and 0.25 mg/ml acepromazine cocktail. For all surgical 
procedures, mice were anesthetized with 100 mg/kg ketamine, 15 mg/kg 
xylazine, and 2.5 mg/kg acepromazine in a 0.9% NaCl solution (ketamine 
cocktail).
Sciatic nerve injection. Adult female Fischer 344 rats (150–165 g) were 
anesthetized with isoflurane, an incision was made along the hindlimb 
immediately caudal and parallel to the femur, and the sciatic nerve was 
exposed. A volume of 2 μl of 0.1% EtBr in PBS was injected unilaterally 
to the sciatic nerve (1 μl/branch). PBS was injected into the contralateral 
sciatic nerve. Viral particles (2 μl) at concentrations of 2.0 × 109 of single-
stranded rAAV1-GFP (n = 4), scAAV1-GFP (n = 5), or scAAV2-GFP (n = 
3) were injected to the sciatic nerve (1 μl/branch) 1 week following 0.1% 
EtBr or PBS injections. All injections were made with a 36 GA injection 
needle (World Precision Instruments, Sarasota, FL) at a rate of 1 μλ/min 
and the needle was held in place for an additional 15 seconds following 
injection. Two weeks after AAV-GFP injection, animals were transcardi-
ally perfused with ice-cold PBS followed by 4% paraformaldehyde. Spinal 
columns were postfixed in 4% paraformaldehyde overnight then trans-
ferred to a 30% sucrose solution before cryostat sectioning of the lumbar 
enlargement (horizontal; 35 μm) and L4 and L5 dorsal root ganglia (30 μm; 
embedded in 10% gelatin). Sciatic nerves embedded in 10% gelatin were 
cryostat-sectioned transversely (30 μm) through the center of the glio-
toxic lesion. For time course studies, 48 animals divided into two sets were 
injected unilaterally with 0.1% EtBr. One set, used for myelin staining of 
sciatic nerve, was transcardially perfused (as above) at the following time 
points: 15 minutes, 4, 8, 12, 16, or 24 hours after EtBr injection (n = 4 at 
each time point). The other set was retrogradely transduced with scAAV1-
GFP at the same time points following EtBr injection (n = 4 at each time 
point) and transcardially perfused 2 weeks after viral transduction.
Myelin staining. Myelin staining was performed as described.18 Briefly, 
sections washed twice in dH2O then twice in 0.025 mol/l phosphate-buffer 
with 0.9% NaCl (working solution) were incubated for 1 hour at room 
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temperature in 0.2% gold (III) chloride solution with 0.0075% H2O2 in 
working solution. Sections were washed twice more in working solution, 
then incubated for 5 minutes in 5% sodium thiosulfate at room tempera-
ture before three final washes in dH2O.
Immunohistochemistry. Free floating sections were blocked for 1 hour at 
room temperature in Tris-buffered saline Tween-20 with 5% donkey serum 
and stained overnight at 4 °C with the following primary antibodies: rab-
bit anti-GFP (1:1,500 fluorescent, 1:6,000 light level), mouse anti-NF200 
(1:2,000; Invitrogen, Carlsbad, CA) and mouse anti-NF200 (1:500; Sigma-
Aldrich, St Louis, MO; dorsal root ganglia sections). Secondary antibodies 
were Alexa Fluor 488 and 594 conjugated donkey IgGs (1:250; Invitrogen) 
and biotinylated donkey anti-rabbit IgG (1:250; Jackson ImmunoResearch 
Laboratories, West Grove, PA). For light level immunohistochemistry, 
biotinylated IgG-labeled sections were incubated in avidin:biotinylated 
enzyme complex (Vector Labs, Burlingame, CA) for 1 hour at room tem-
perature before development with 3,3′-diaminobenzidine.
Analysis of tissue sections. Total GFP immunoreactive motor and sen-
sory neurons were counted in every 7th section. Nonstereological quan-
tification methods were used because our intention was to compare the 
proportional efficiency of retrograde transduction within animal subjects 
(comparing the intact side to the transiently demyelinated side using sta-
tistical pair-wise comparisons), rather than defining total numbers of 
transduced neurons. Photographs of gold (III) chloride stained trans-
verse sciatic nerve sections were digitally acquired with PictureFrame 
software (Optronics, Goleta, CA), as were images of horizontal sections 
of dorsal lumbar spinal cord. For quantification, images were inverted 
and thresholded, and pixel density was quantified using ImageJ (NIH, 
Bethesda, MD).
NT-3 elevation via retrograde transduction. Nine additional animals 
were utilized to assay NT-3 elevation following EtBr injection and retro-
grade transduction. Animals were injected bilaterally with either 0.1% EtBr 
in PBS (n = 6) or PBS alone (n = 3). Three of the EtBr-treated animals 
and the PBS-injected animals were then retrogradely transduced with 
4.0 × 109 viral particles (4 μl total, 1 μl/branch) of scAAV1-NT-3 1 week 
later. All animals were perfused with ice-cold saline 3 weeks after EtBr or 
PBS injection. Ventral gray matter was dissected and frozen over dry ice 
in prechilled, preweighed 1.5 ml tubes. The tissue was homogenized using 
a sonicator in ice-cold PBS (15 mg tissue/ml) with 1.44% wt/vol NaCl, 
0.5% wt/vol bovine serum albumin, 0.1 mmol/l phenylmethanesulfonyl-
fluoride, 0.9 mmol/l aprotinin, 5 mmol/l EDTA, and 0.1% Triton X-100. 
Samples were centrifuged at 14 k.r.p.m. for 30 minutes at 4 °C and NT-3 
levels in supernatants were assayed by enzyme-linked immunosorbent 
assay (Promega, Madison, WI).
Animal surgery for in vivo imaging. Four adult male BL6 mice were 
anesthetized with ketamine cocktail. The sciatic nerve was exposed as 
described above and injected bilaterally with 2.0 μl of 0.1% EtBr (0.5 μl/
branch). One week later, animals were retrogradely transduced with 2.0 × 
109 viral particles (2 μl total, 0.5 μl/branch). After 2 weeks, animals were 
anesthetized with ketamine cocktail and were maintained under anesthe-
sia with one-quarter of this dose each hour for the duration of the imaging 
session. The midline of the back was shaved and sterilized with 70% etha-
nol. A 1-cm long midline dermal incision was made, the vertebral muscles 
were carefully removed and a laminectomy at T10 was made to expose the 
spinal cord. The spinal column was stabilized with customized Narishige 
spinal cord clamps and head holding adaptors mounted on a steel plate 
as described.22 Briefly, the clamps were placed on both the T9 and T11 
vertebrae to stabilize the spinal column. The head was placed in the head 
holding adaptor and the tail was clamped so that the mouse maintained a 
relatively level position. A well of petroleum jelly was created around the 
exposed spinal cord and filled with artificial cerebrospinal fluid in order to 
accommodate the immersion lens.
In vivo imaging of retrogradely transduced sensory neurons. After 
the mouse was secured in the stabilization device, it was then placed in 
a heat-controlled chamber underneath a customized FV300 Olympus 
microscope (Olympus America Inc., Center Valley, PA) as described.22 
Imaging was performed with a Spectra Physics Mai-Tai laser tuned to 
920 nm for two-photon excitation of YFP. In order to obtain a map of 
the entire imaging area an Olympus 10× (0.3 numerical aperature) water-
immersion lens was used. To examine labeled axons in finer detail, an 
Olympus 40× (0.8 numerical aperature) water-immersion lens was used. 
Images were acquired with Olympus FluoView software. Z-stacks were 
taken every 10 μm with the 10× objective, and every 1 μm with the 40× 
objective throughout the entire focal area. The final images are a com-
pression of all z-stacks to recreate the three-dimensional space in a two-
dimensional image. During the acquisition phase, laser power and offset 
were set to minimize background. For postacquisition image processing, 
brightness and contrast were adjusted using Adobe Photoshop.
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